Clinical trials: Small Cell Lung Carcinoma (SCLC)
1-5 Brain Metastases From Non-Small Cell Lung Cancer
Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
The study is a prospective, randomly controlled phase II trial, designed to test the efficacy, safety and neurocognitive outcomes of a medical device, the NovoTTF-100A, in the treatment of NSCLC patients with controlled systemic…
- Trial name
- NCT01755624
- Testing
- NovoTTF-100A device, Best Standard of Care
- Where
- 7 sites in Czechia, France and 3 more
- Volunteers
- 18 people
- Sponsor
- NovoCure Ltd.
Non Small Cell Lung Cancer Recurrent
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of…
- Trial name
- NCT05842018
- Testing
- Toripalimab, Anlotinib and Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Hepatocellular, Gastric Adenocarcinoma
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in…
- Conditions
- Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer
- Trial name
- VALUE-CHECK (NCT06422403)
- Testing
- Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C
- Where
- Singapore
- Volunteers
- 360 people
- Sponsor
- National University Hospital, Singapore
Ovarian Cancer, Non-small Cell Lung Cancer
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with…
- Trial name
- NAPISTAR1-01 (NCT06303505)
- Testing
- TUB-040, Bevacizumab
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells.
- Trial name
- NCT00002822
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Medical Research Council
Extensive Small Cell Lung Cancer
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.
- Trial name
- NCT06125041
- Testing
- Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Qianfoshan Hospital
Lung Cancer, Nonsmall Cell
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No…
- Trial name
- NCT02991651
- Testing
- IRX4204, erlotinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Io Therapeutics
Non-Small Cell Lung Cancer
First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001
This phase I, first-in-human dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary…
- Trial name
- NCT02896231
- Testing
- PLB1001
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Non-small Cell Lung Cancer
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the effect on toxicity of the addition of CS 1008 to a platinum based chemotherapy regimen on the progression-free survival (PFS) in subjects with stage IIIB wet or stage IV NSCLC.
- Trial name
- NCT00991796
- Testing
- CS-1008, Paclitaxel, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal…
- Trial name
- NCT03003962
- Testing
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 92 sites in United States, Australia and 10 more
- Volunteers
- 669 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2
Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.
- Trial name
- NCT00273494
- Testing
- Surgery
- Where
- Denmark
- Volunteers
- 406 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Small Cell Lung Cancer
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006…
- Trial name
- NCT07559929
- Testing
- DXC006, Toripalimab, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Non-small Cell Lung Cancer Stage I
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
This is a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel…
- Trial name
- NCT03603002
- Testing
- Post-SABR Biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+)…
- Trial name
- NCT04075396
- Testing
- Lazertinib
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Carcinoma, Non-small Cell Lung Cancer
Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)
This is an open label, multi-center, randomized control phase II trial, to compare the efficacy and safety of sintilimab combined with anlotinib versus standard platinum-based chemotherapy as a first-line treatment in advanced…
- Trial name
- NCT04124731
- Testing
- sintilimab plus anlotinib, Chemotherapy
- Volunteers
- 98 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models
Investigators combined the clinical and radiomics characteristics of resectable non-small cell lung cancer patients to construct an accurate model for preoperative prediction of mediastinal lymph node status.
- Trial name
- NCT06768853
- Testing
- Lymph node dissection based on the guidelines, Lymph node dissection based on the model
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongnan Hospital
NSCLC
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of…
- Trial name
- NCT06094296
- Testing
- BMS-986315, Nivolumab, Pemetrexed
- Where
- 8 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and prevent the spread of cancer to the brain. It is not yet known if standard-dose radiation therapy is more effective than high-dose radiation therapy in…
- Trial name
- NCT00005062
- Testing
- radiation therapy
- Where
- 93 sites in United States, Australia and 26 more
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.